title: T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
abstract: OBJECTIVE
  The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia.
  
  
  RESULTS
  CD123 is a leukemia-associated antigen that expresses at high levels in leukemic stem cells and leukemic blasts and low level in normal hematopoietic stem/progenitor cells. Immune-based therapies targeting CD123 are being developed. Preclinical data suggest that CD123 CAR T cells exhibit potent antileukemic activity and various impacts on normal hematopoiesis.
  
  
  CONCLUSIONS
  CD123 is an attractive surface target for novel antileukemic therapies. CD123 CAR T-cell-based immunotherapy is a promising treatment for patients with relapsed or refractory acute myeloid leukemia.
authors.affiliation: aKite Pharma, Inc., Santa Monica bDepartment of Hematology & Hematopoietic Cell Transplantation cDepartment of Cancer Immunotherapeutics dDepartment of Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
authors.forename: Armen
authors.initials: A
authors.lastname: Mardiros
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Lihua E
authors.initials: LE
authors.lastname: Budde
mesh_terms: D006801:Humans; D007167:Immunotherapy; D053650:Interleukin-3 Receptor alpha Subunit / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D011948:Receptors, Antigen, T-Cell